Request Demo
Last update 08 May 2025
GeneSys Biologics Pvt Ltd.
Last update 08 May 2025
Overview
Tags
Immune System Diseases
Endocrinology and Metabolic Disease
Biosimilar
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
No Data
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
CTRI/2023/03/050804
A Randomized, Assessor Blind, Active-Controlled, Multicenter, Parallel Group, Non-Inferiority Study to compare the Efficacy and Safety of GEN1501 (Insulin Glargine (r-DNA Origin) Injection 100 Units/mL) of GeneSys Biologics Pvt. Ltd., India with LANTUS® (Insulin Glargine (r-DNA Origin) Injection 100 Units/mL) in patients with Type 2 Diabetes Mellitus on Uncontrolled Oral Antidiabetic therapy (OAD)
CTRI/2022/11/047188
A double blind, balanced, randomized, two-treatment, two-sequence, two-period, single dose, cross over, pharmacokinetic and pharmacodynamic bioequivalence study of GEN1503PR (Insulin Aspart (r-DNA origin) Injection) 100 U/mL of GeneSys Biologics Pvt. Ltd. Hyderabad, India and NovoRapid® (Insulin Aspart (r-DNA origin) Injection) 100 U/mL of Novo Nordisk, in healthy adult, male human subjects using Euglycemic clamp technique under fasting conditions
CTRI/2020/09/027956
An open label, randomized, two-treatment, two-sequence, four-period, single-dose, full replicate crossover bioequivalence study of GEN1501 (Insulin Glargine Injection) 100 U/mL of GeneSys Biologics Pvt. Ltd., Hyderabad, India and LANTUS�® (Insulin Glargine Injection) 100 U/mL of Sanofi-Aventis, in healthy male, adult, human subjects under fasting conditions. - GEN1501
100 Clinical Results associated with GeneSys Biologics Pvt Ltd.
Login to view more data
Login to view more data
100 Deals associated with GeneSys Biologics Pvt Ltd.
Login to view more data
100 Translational Medicine associated with GeneSys Biologics Pvt Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 13 Jun 2025
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
3
Other
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free